-transparent.png){kind=logo}
The mechanisms by which B16, 3LL and MH134 tumor cells induce platelet aggregation were studied. The B16 and 3LL tumors, which have high or moderate procoagulant activities, aggregated platelets only in the presence of Ca2+ and plasma factors. MH134, which had much lower procoagulant activity, aggregated platelets even in the absence of these factors. The induction of aggregation by B16 and 3LL could be prevented by thrombin inhibitors but not by the ADP scavenger, suggesting that thrombin, generated by procoagulant activities of tumor cells themselves, might play a major role in initiating aggregation. MH134-induced aggregation was not affected by any of the inhibitors, indicating that the mechanisms by which MH134 initiate platelet aggregation are independent of both thrombin and ADP.
A Tohgo, and
N Tanaka, and
S Ashida, and
H Ogawa
January 1991,
Bulletin du cancer,
A Tohgo, and
N Tanaka, and
S Ashida, and
H Ogawa
April 1980,
Cancer research,
A Tohgo, and
N Tanaka, and
S Ashida, and
H Ogawa
September 1977,
The Journal of laboratory and clinical medicine,
A Tohgo, and
N Tanaka, and
S Ashida, and
H Ogawa
January 1966,
Hemostase,
A Tohgo, and
N Tanaka, and
S Ashida, and
H Ogawa
January 1977,
Thrombosis research,
A Tohgo, and
N Tanaka, and
S Ashida, and
H Ogawa
April 1977,
Laboratory investigation; a journal of technical methods and pathology,
A Tohgo, and
N Tanaka, and
S Ashida, and
H Ogawa
May 1996,
Acta obstetricia et gynecologica Scandinavica,
A Tohgo, and
N Tanaka, and
S Ashida, and
H Ogawa
July 1986,
Thrombosis research,
A Tohgo, and
N Tanaka, and
S Ashida, and
H Ogawa
January 1982,
Progress in clinical and biological research,
A Tohgo, and
N Tanaka, and
S Ashida, and
H Ogawa
September 2001,
Current opinion in hematology,
